NCT05229068View on ClinicalTrials.gov

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 11, 2022

Primary Completion Date

November 6, 2023

Study Completion Date

October 24, 2024

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV MAT

Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.

Trial Locations (2)

59804

GSK Investigational Site, Missoula

68701

GSK Investigational Site, Norfolk

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY